SPHK1 and neoplasm: For example, specific SK1 inhibitors developed as drug candidates dramatically reduced S1P levels but did not slow cancer cell proliferation in vitro or limit tumor growth in vivo (Schnute et al, 2012; Rex et al, 2013).